Skip to main content

Table 3 Distribution of 38-gene HGF signature expression within non-basal-like tumors (N = 1338), Carolina Breast Cancer Study, 1993–2013

From: Hepatocyte growth factor pathway expression in breast cancer by race and subtype

  Non-basal-like HGF-negative, N (%) Non-basal-like HGF-positive, N (%) Non-basal-like multivariable RFD (95% CI)
Total 1230 108 1338
Agea    
 < 40 years old 141 (88%) 20 (13%) 5.40% (0.12, 10.67)
 40–49 years old 458 (91%) 43 (9%) 2.06% (− 0.86, 4.98)
 ≥ 50 years old 631 (93%) 45 (7%) Referent
Raceb    
 Black 561 (89%) 69 (11%) 5.35% (2.45, 8.26)
 Non-black 669 (94%) 39 (6%) Referent
Gradec    
 III 296 (85%) 53 (15%) 10.37% (6.31, 14.42)
 I/II 655 (96%) 25 (4%) Referent
Stagec    
 Stage III/IV 193 (86%) 31 (14%) 7.12% (2.25, 1.00)
 Stage II 562 (92%) 52 (8%) 2.24% (− 0.60, 5.10)
 Stage I 458 (95%) 24 (5%) Referent
Reproductive historyc    
 Nulliparous 198 (93%) 14 (7%) − 2.45% (− 6.32, 1.42)
 Parous, breastfed 515 (90%) 39 (7%) − 1.64% (− 4.7, 1.42)
 Parous, never breastfed 517 (90%) 55 (10%) Referent
Risk of recurrence scorec    
 High ROR-PT 128 (79%) 34 (21%) 13.56% (7.09, 20.02)
 Low/medium ROR-PT 1063 (94%) 70 (6%) Referent
  1. aRelative frequency differences (RFDs) adjusted for race
  2. bAdjusted for age
  3. cAdjusted for race and age
  4. ROR-PT, risk of recurrence score incorporating subtype, proliferation, and tumor size